Oscotec Inc.

A039200

KR7039200001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 13/05/2024 BST			5-day change	1st Jan Change
30,200 ^KRW	+5.96%		+2.72%	+31.02%

02-23	Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's Disease	CI
2023	Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease	CI

Oscotec Inc. announced that it has received KRW 10 billion in funding from a group of investors

December 25, 2017

On December 26, 2017, Oscotec Inc. (KOSDAQ:A039200) closed the transaction.

Latest news about Oscotec Inc.

Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's Disease	02-23	CI
Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease	14/09/23	CI
Oscotec Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib	24/02/23	CI
Oscotec Inc. announced that it has received KRW 29.9999073 billion in funding from Tiger Asset Management Discretionary Investment Co., Ltd., Meritz Securities Co., Ltd., Investment Arm, Asset One Asset Management	31/03/22	CI
Oscotec Inc. announced that it expects to receive KRW 29.9999073 billion in funding from Tiger Asset Management Discretionary Investment Co., Ltd., Meritz Securities Co., Ltd., Investment Arm, Asset One Asset Management	23/03/22	CI
Oscotec Inc. and Beactica Therapeutics AB Announces License and Collaboration Agreement to Develop New Cancer Drug	02/03/21	CI
Oscotec Inc. announced that it has received KRW 21.9999934 billion in funding from E&Investment,Inc.	25/12/19	CI
Oscotec Inc. announced that it expects to receive KRW 21.9999934 billion in funding from E&Investment,Inc.	17/12/19	CI
Oscotec Inc. announced that it has received KRW 19.9999584 billion in funding from E&INVESTMENT INC., Samsung Securities Co. Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm, AJU IB INVESTMENT Co., Ltd.	10/09/18	CI
Oscotec Inc. announced that it expects to receive KRW 19.9999584 billion in funding from E&INVESTMENT INC., Samsung Securities Co. Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm, AJU IB INVESTMENT Co., Ltd.	03/09/18	CI
Oscotec Inc. announced that it has received KRW 10 billion in funding from a group of investors	25/12/17	CI
Oscotec Inc. announced that it expects to receive KRW 10 billion in funding from a group of investors	21/12/17	CI
Oscotec Inc.(KOSDAQ:A039200) added to S&P Global BMI Index	19/09/16	CI
Oscotec Inc. announced that it has received KRW 6 billion in funding from Songhyun Investment Ltd., AJU IB INVESTMENT Co., Ltd., and another investor.	02/12/15	CI
Oscotec Inc. announced that it expects to receive KRW 6 billion in funding from Songhyun Investment Ltd., AJU IB INVESTMENT Co., Ltd., and another investor.	30/11/15	CI
Oscotec Inc. announced that it has received KRW 2 billion in funding from Synergy Partners Co., Ltd.	09/01/15	CI
Oscotec Inc. announced that it expects to receive KRW 2 billion in funding from Synergy Partners Co., Ltd.	08/01/15	CI
Oscotec Inc. announced that it has received KRW 4 billion in funding.	30/04/12	CI
Oscotec Inc. announced that it expects to receive KRW 4 billion in funding.	26/04/12	CI

Oscotec Inc.,Ltd is a Korea-based company mainly engaged in the manufacture of functional medical materials and related products. The Company operates its business through three divisions: new medicines division, functional material products division and dental bone graft division. Its new medicines division provides osteoporosis drugs, arthritis drugs and periodontal disease drugs. Its functional material products division provides functional materials and food used for promoting bone growth and periodontal health. Its dental bone graft division provides bone graft materials, membranes and centrifuges. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Oscotec Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30,200 KRW

Average target price

46,500 KRW

Spread / Average Target

+53.97%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
OSCOTEC INC.	+31.02%	845M
MERCK KGAA	+15.09%	74.45B
KYOWA KIRIN CO. LTD.	+11.35%	9.18B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+54.35%	5.03B
SK BIOPHARMACEUTICALS CO., LTD.	-12.85%	5.02B
YUHAN CORPORATION	+1.60%	3.82B
BETTA PHARMACEUTICALS CO., LTD.	-20.85%	2.41B
INDIVIOR PLC	+16.88%	2.39B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.25%	2.27B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.62%	2.26B

Specialty & Advanced Pharmaceuticals

Oscotec Inc.

Equities

A039200

KR7039200001

Pharmaceuticals

Oscotec Inc. announced that it has received KRW 10 billion in funding from a group of investors

Latest news about Oscotec Inc.

Chart Oscotec Inc.

Company Profile

Income Statement Evolution

Ratings for Oscotec Inc.

Analysts' Consensus

Annual profits - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals